Five things for pharma marketers to know: Tuesday, February 20, 2018

Share this content:

A federal judge has voided an order requiring Gilead to pay Merck $2.5 billion over a patent dispute. The reversal followed a jury ruling, which found that Gilead's hepatitis C drugs Sovaldi and Harvoni infringed on a patent held by Merck. In a statement, Merck said that it planned to appeal. (Reuters)

Promising results for Aimmune Therapeutics' peanut allergy therapy. In a phase 3 trial, 67% of patients ages four to 17 could tolerate a 600-mg dose or more of peanut protein at the end of the study, compared with 4% of those who received a placebo. The company plans to file an application for the drug with the FDA by the end of the year. (Endpoints)

AstraZeneca has won FDA approval for a key cancer drug. The agency signed off on the expanded use of the company's immunotherapy drug Imfinzi for treating patients with stage three, inoperable mid-stage lung cancer that has not spread to other parts of the body. (Financial Times)

The FTC's battle to have Abbvie pay $1.3 billion to consumers is shaping up to be a referendum on the agency's ability to police generic drugs. The agency wants the drug company to pay the sum for delaying generic versions of AndroGel. (Wall Street Journal)

Many Americans lack basic dental care through Medicaid. The lack of coverage can lead to a range of other serious health problems, such as heart disease and risk of stroke. There are also links between poor dental health and the loss of teeth and other issues. (New York Times)
Share this content:
Scroll down to see the next article